Exelixis (EXEL) Non-Current Debt (2010 - 2016)
Exelixis (EXEL) posted quarterly Non-Current Debt of $80.0 million for Q1 2016, little changed year-over-year from $80.0 million in Q2 2015, and little changed quarter-over-quarter from $80.0 million in Q4 2015.
Exelixis (EXEL) Non-Current Debt (2010 - 2016) Analysis & Trends
Exelixis' Non-Current Debt history runs 7 years deep, the most recent figure standing at $80.0 million for Q1 2016.
- In Q1 2016, Non-Current Debt changed 0.0% year-over-year to $80.0 million; the TTM figure through Mar 2016 stood at $80.0 million (changed 0.0% YoY), while the FY2015 annual figure was $80.0 million, changed 0.0% from the prior year.
- Non-Current Debt for Q1 2016 stood at $80.0 million, roughly flat from $80.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $84.5 million in Q1 2012, with the low at $80.0 million in Q3 2014.
- The 5-year median for Non-Current Debt is $80.2 million (2014), against an average of $81.0 million.
- The sharpest annual moves came in 2012 and 2015: Non-Current Debt declined 3.72% in 2012, then changed 0.0% in 2015.
- Exelixis' Non-Current Debt stood at $82.1 million in 2012, then decreased by 2.15% to $80.3 million in 2013, then slipped by 0.41% to $80.0 million in 2014, then changed by 0.0% to $80.0 million in 2015, then changed by 0.0% to $80.0 million in 2016.
- Business Quant data shows EXEL's Non-Current Debt at $80.0 million in Q1 2016, $80.0 million in Q4 2015, and $80.0 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 80.00 Mn |
| Dec 31, 2015 | 80.00 Mn |
| Sep 30, 2015 | 80.00 Mn |
| Jun 30, 2015 | 80.00 Mn |
| Mar 31, 2015 | 80.00 Mn |
| Dec 31, 2014 | 80.00 Mn |
| Sep 30, 2014 | 80.00 Mn |
| Jun 30, 2014 | 80.06 Mn |
| Mar 31, 2014 | 80.22 Mn |
| Dec 31, 2013 | 80.33 Mn |
| Sep 30, 2013 | 80.76 Mn |
| Jun 30, 2013 | 81.13 Mn |
| Mar 31, 2013 | 81.61 Mn |
| Dec 31, 2012 | 82.09 Mn |
| Sep 30, 2012 | 82.89 Mn |
| Jun 30, 2012 | 83.68 Mn |
| Mar 31, 2012 | 84.47 Mn |
| Dec 31, 2011 | 85.26 Mn |
| Sep 30, 2011 | 85.79 Mn |
| Jun 30, 2011 | 86.57 Mn |